BCDA BioCardia, Inc.
Price Chart
Executive Summary
BioCardia reported Q1 2026 EPS of -$0.21, missing consensus of -$0.17 by 23.5%, while revenue remained zero. However, the company made significant regulatory progress: Japan's PMDA indicated clinical data is likely sufficient for market clearance, and FDA supported the ongoing CardiAMP HF II trial as a confirmatory study. Cash burn continues with $951K on hand.
Actionable Insight
Regulatory catalysts (Japan PMDA and FDA support) are the primary drivers, potentially outweighing the EPS miss. Monitor upcoming milestones: Euro PCR presentation (May 20) and Japan Shonin submission (Q4 2026). Cash runway is limited; likely need financing within 1-2 quarters.
Key Facts
- Q1 2026 EPS -$0.21 vs consensus -$0.17 (23.5% miss)
- Zero revenue; pre-revenue clinical-stage biotech
- Japan PMDA preliminary advisory record indicates likely market clearance for CardiAMP cell therapy
- FDA Q-Sub meeting: no safety concerns, supports CardiAMP HF II trial as confirmatory study
- Cash and cash equivalents $951K, down from $2.5M in Dec 2025
- Net loss $2.3M in Q1 2026 vs $2.7M in Q1 2025
Financial Impact
EPS miss of 23.5% on a small base; cash position low (~$1M)
Risk Factors
- Cash runway only ~$1M; substantial doubt about going concern without additional financing
- Japan approval is not guaranteed; further questions from PMDA could delay
- Dilution risk from potential future equity offerings
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295791 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 15, 2026
6d ago
|
8-K
| $1.09 awaiting T+5 | awaiting T+5 | — | $0.9215 (−15.07%) |
|
May 15, 2026
6d ago
|
Press Release
| $1.09 awaiting T+5 | awaiting T+5 | — | $0.9215 (−15.07%) |
|
May 11, 2026
9d ago
|
Press Release
| $1.12 $0.9000 | ▼ −19.64% | ▼ −19.72% | $0.9215 (−17.72%) |
|
May 8, 2026
13d ago
|
8-K
| $1.11 $1.09 | ▼ −1.80% | ▼ −3.27% | $0.9215 (−16.98%) |
|
Apr 28, 2026
23d ago
|
8-K
| $1.14 $1.13 | ▼ −0.88% | ▼ −2.57% | $0.9215 (−19.17%) |
|
Apr 20, 2026
4w ago
|
Press Release
| $1.25 $1.16 | ▼ −7.20% | ▼ −8.11% | $0.9215 (−26.28%) |
|
Apr 15, 2026
5w ago
|
8-K
| $1.19 $1.17 | ▲ +1.68% | ▲ +2.66% | $0.9215 (+22.56%) |
|
Apr 2, 2026
7w ago
|
Press Release
| $1.20 $1.18 | ▼ −1.67% | ▼ −5.29% | $0.9215 (−23.21%) |
|
Apr 2, 2026
7w ago
|
8-K
| $1.20 $1.18 | ▼ −1.67% | ▼ −5.29% | $0.9215 (−23.21%) |
|
Mar 24, 2026
8w ago
|
Press Release
| $1.20 $1.16 | ▲ +3.33% | ▲ +3.09% | $0.9215 (+23.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access